LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Average Rating of “Moderate Buy” by Brokerages

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has been assigned a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $94.57.

A number of brokerages recently weighed in on LMAT. JMP Securities increased their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 20th. Cantor Fitzgerald started coverage on LeMaitre Vascular in a report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price target on the stock. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Barrington Research raised their target price on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $93.00 price target (up previously from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st.

LeMaitre Vascular Trading Up 0.4 %

LeMaitre Vascular stock opened at $105.80 on Thursday. LeMaitre Vascular has a 12 month low of $51.70 and a 12 month high of $109.58. The stock has a fifty day simple moving average of $94.86 and a two-hundred day simple moving average of $87.55. The firm has a market cap of $2.38 billion, a price-to-earnings ratio of 57.81, a PEG ratio of 2.62 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05. The company had revenue of $54.82 million for the quarter, compared to analysts’ expectations of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. LeMaitre Vascular’s revenue was up 15.6% compared to the same quarter last year. During the same period last year, the firm posted $0.33 earnings per share. On average, equities research analysts forecast that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st will be given a dividend of $0.16 per share. The ex-dividend date is Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.60%. LeMaitre Vascular’s payout ratio is currently 34.97%.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the sale, the director now owns 2,278 shares in the company, valued at approximately $231,148.66. This represents a 62.21 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 10.79% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On LeMaitre Vascular

A number of hedge funds have recently made changes to their positions in LMAT. NBC Securities Inc. lifted its holdings in shares of LeMaitre Vascular by 73.2% in the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 183 shares in the last quarter. GAMMA Investing LLC increased its holdings in LeMaitre Vascular by 57.0% in the 2nd quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock valued at $45,000 after acquiring an additional 199 shares during the last quarter. West Oak Capital LLC bought a new position in shares of LeMaitre Vascular during the 2nd quarter valued at about $58,000. USA Financial Formulas purchased a new position in shares of LeMaitre Vascular during the third quarter valued at about $60,000. Finally, nVerses Capital LLC increased its holdings in shares of LeMaitre Vascular by 33.3% in the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after purchasing an additional 200 shares during the last quarter. Institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.